Kura Oncology Inc. (NASDAQ:KURA)’s share price rose 1.9% on Wednesday . The company traded as high as $4.57 and last traded at $4.36, with a volume of 80,641 shares changing hands. The stock had previously closed at $4.28.

KURA has been the topic of a number of research reports. Oppenheimer Holdings Inc. reiterated an “outperform” rating and issued a $16.00 target price on shares of Kura Oncology in a report on Tuesday, June 21st. Zacks Investment Research upgraded Kura Oncology from a “hold” rating to a “buy” rating and set a $3.75 target price on the stock in a report on Wednesday, July 13th.

The firm’s 50-day moving average price is $3.67 and its 200 day moving average price is $3.64. The firm’s market cap is $80.40 million.

Kura Oncology (NASDAQ:KURA) last announced its quarterly earnings data on Wednesday, August 10th. The company reported ($0.36) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.34) by $0.02. Analysts forecast that Kura Oncology Inc. will post ($1.70) earnings per share for the current fiscal year.

Kura Oncology, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood cancers.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.